In vivo, CA not only mitigated hallmark pathological features of asthma, such as inflammation and fibrosis, but also modulated the expression of core ferroptosis regulators GPX4 and SLC7A11, positioning it as a multi-faceted inhibitor with therapeutic potential for asthma and other ALOX15-associated diseases [106]. Here, GPX4 is linked to asthma.